Crinetics Pharmaceuticals Shares Rise 6.8%

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) has announced the early release of late-breaking abstracts for the upcoming Endocrine Society’s annual meeting (Endo 2024). The abstract for the phase 2, open-label study of atumelnant* (CRN04894) in congenital adrenal hyperplasia contained summary data for four subjects at the time of submission, with plans to present additional data from a total of six subjects in cohort 1 and additional subjects in cohort 2 at Endo 2024. The more comprehensive data set will be presented during the late-breaking poster presentation session on June 3, 2024, at 12:00 – 1:30 pm ET.

Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. The company's drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

One of the company's investigational drugs, paltusotine, is in phase 3 clinical development for acromegaly and in phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Additionally, atumelnant (CRN04894), another investigational drug, is completing phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease.

This early release of abstracts provides a glimpse into the ongoing research and development efforts at Crinetics Pharmaceuticals, offering a preview of the data that will be presented at the upcoming Endo 2024 meeting. It also underscores the company's commitment to advancing novel therapeutics for a range of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes, and obesity. Today the company's shares have moved 6.8% to a price of $52.85. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS